AFFY  Affymax Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Current Price

+0.000 (+0.000%)

Book Price

Overvalued by 333.10%
Financial Institution

Company Metrics

  • P/E 1.134
  • P/S 83.016
  • P/B 0.674
  • EPS 0.082
  • Dividend 0.000 / 0.000 %
  • Avg. Vol. 51,041.00
  • Shares 37.53M
  • Market Cap. 3.49M

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Technical Insights on Affymax, Inc. (OTCMKTS: AFFY)
MicroCap Daily - Nov 3, 2014
Affymax, Inc. (OTCMKTS: AFFY) has been moving in a bearish trend since July, 2014 trading around $0.10 per share, but the stock did saw a major bullish rally in the months of January to April , 2014 when its touched its high of $1.04 at a trading ...
Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share.
Affymax, Inc. (AFFY): Affymax Likely Worthless: Omontys Kills At Least 9x More ...
Seeking Alpha - Aug 28, 2013
Affymax, Inc. (OTCPK:AFFY) is a shell company that owns potential future royalty and milestone payments associated with the recently recalled drug Omontys (peginesatide).
Affymax, Inc. (AFFY): Affymax: Emerging Data Supports Conclusion Omontys ...
Seeking Alpha - Nov 12, 2013
The FDA data, combined with the lack of commentary about Omontys on Fresenius' (NYSE:FMS) or Takeda's (OTCPK:TKPHF) latest earnings calls and the cash burn at Affymax (OTCPK:AFFY), all lead us to believe that the end is near for Affymax.
Affymax, Inc. (OTCMKTS:AFFY) Crashes After Losing Partner
HotStocked - Jun 17, 2014
Yesterday's market session was a real disaster for Affymax, Inc. (OTCMKTS:AFFY, AFFY message board). Once the 8-K announcing that the partnership AFFY had with Takeda has been terminated affected the market, the company lost 54.55% of its share ...
Lawsuit on Behalf of Affymax, Inc. (AFFY) Investors Over Alleged Misleading ...
GlobeNewswire (press release) - Mar 4, 2013
SAN DIEGO, March 4, 2013 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of purchasers of Affymax, Inc. (AFFY) common stock during the period between December 8, 2011 and February 22, 2013 ...
The end for Affymax (AFFY)
Seeking Alpha - Jun 24, 2014
With no hope for a return to the market for Omontys, Affymax's (AFFY) BOD approves the liquidation and dissolution of the company, subject to shareholder approval.
Affymax Board Announces Decision to Dissolve the Company - Business Wire (press release)
Affymax Board Approves Dissolving Troubled Company - Genetic Engineering News
Delisting of Securities of Telestone Technologies Corp, Affymax, Inc., Exide ...
GlobeNewswire (press release) - Jul 18, 2013
Telestone Technologies Corp.'s stock was suspended on June 03, 2013 and has not traded on NASDAQ since that time. NASDAQ also announced that it will delist the common stock of Affymax, Inc. Affymax, Inc.'s stock was suspended on June 06, 2013 and ...
Affymax, Inc.'s Pain Becomes Amgen Inc.'s Gain
iStockAnalyst (press release) - Feb 25, 2013
(By Mani) Affymax, Inc. (NASDAQ: AFFY) announced a national voluntary recall of all lots of Omontys after reports of serious hypersensitivity reactions including anaphylaxis.
Affymax stock plunges 85 percent on drug recall - Reuters
Takeda, Affymax Recall Omontys Drug After `Serious' Reactions - Bloomberg
Here is What Hedge Funds Think About Affymax, Inc. (AFFY)
Insider Monkey (blog) - Jun 10, 2013
Is Affymax, Inc. (NASDAQ:AFFY) a first-rate investment now? The smart money is taking a pessimistic view. The number of long hedge fund positions were cut by 4 recently.